Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
60 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Optic Neuritis - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Optic Neuritis - Pipeline Review, H1 2015’, provides an overview of the Optic Neuritis’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Optic Neuritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Optic Neuritis and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Optic Neuritis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Optic Neuritis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Optic Neuritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Optic Neuritis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Optic Neuritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Optic Neuritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Optic Neuritis Overview 6 Therapeutics Development 7 Pipeline Products for Optic Neuritis - Overview 7 Pipeline Products for Optic Neuritis - Comparative Analysis 8 Optic Neuritis - Therapeutics under Development by Companies 9 Optic Neuritis - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Optic Neuritis - Products under Development by Companies 13 Optic Neuritis - Companies Involved in Therapeutics Development 14 Biogen Idec Inc. 14 Bionure Farma, S.L. 15 Mallinckrodt plc 16 Meta-IQ ApS 17 Mitsubishi Tanabe Pharma Corporation 18 Neuralstem, Inc. 19 Teijin Pharma Limited 20 Optic Neuritis - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 BN-201 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 corticotropin - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 etomoxir - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 fingolimod hydrochloride - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 immune globulin (human) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 methylprednisolone sodium phosphate liposomal - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 NSI-566 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 opicinumab - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Optic Neuritis - Recent Pipeline Updates 43 Optic Neuritis - Dormant Projects 55 Optic Neuritis - Discontinued Products 56 Optic Neuritis - Product Development Milestones 57 Featured News & Press Releases 57 Jan 08, 2015: Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial In People With Acute Optic Neuritis 57 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 59 Disclaimer 60
List of Tables Number of Products under Development for Optic Neuritis, H1 2015 7 Number of Products under Development for Optic Neuritis - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Optic Neuritis - Pipeline by Biogen Idec Inc., H1 2015 14 Optic Neuritis - Pipeline by Bionure Farma, S.L., H1 2015 15 Optic Neuritis - Pipeline by Mallinckrodt plc, H1 2015 16 Optic Neuritis - Pipeline by Meta-IQ ApS, H1 2015 17 Optic Neuritis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 18 Optic Neuritis - Pipeline by Neuralstem, Inc., H1 2015 19 Optic Neuritis - Pipeline by Teijin Pharma Limited, H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 23 Number of Products by Stage and Mechanism of Action, H1 2015 25 Number of Products by Stage and Route of Administration, H1 2015 27 Number of Products by Stage and Molecule Type, H1 2015 29 Optic Neuritis Therapeutics - Recent Pipeline Updates, H1 2015 43 Optic Neuritis - Dormant Projects, H1 2015 55 Optic Neuritis - Discontinued Products, H1 2015 56
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.